{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/macular-degeneration-age-related/diagnosis/diagnosis/","result":{"pageContext":{"chapter":{"id":"7fd2b2d6-9e86-5014-bc61-f30ce19d5712","slug":"diagnosis","fullItemName":"Diagnosis","depth":2,"htmlHeader":"<!-- begin field 746549c6-ae98-47d0-b6fc-4d801a6ac68d --><h2>When should I suspect age-related macular degeneration?</h2><!-- end field 746549c6-ae98-47d0-b6fc-4d801a6ac68d -->","summary":"","htmlStringContent":"<!-- begin item 699b52bf-44e7-4ff8-9229-3140f5ae056b --><!-- begin field 93289efb-f241-41bd-a57c-d8cc4eea4765 --><ul><li><strong>A person with age-related macular degeneration (AMD) may be asymptomatic,</strong> with retinal signs detected incidentally by an optometrist during a routine eye test. <ul><li>People with early and intermediate AMD may have normal, or near-normal vision. </li></ul></li><li><strong>Suspect AMD in people with <a class=\"topic-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/background-information/risk-factors/\">risk factors</a> for AMD and typical symptoms including:</strong> <ul><li><strong>Blurring or distortion of vision, <strong>typically in people aged over 50 years. </strong> </strong><br><ul><li>With neovascular AMD, visual deterioration can develop quickly — this is often the first symptom. A person may suddenly become unable to read, drive, and see fine detail such as facial expressions and features. </li><li>With geographic atrophy the visual deterioration tends to be gradual — a common presentation is difficulty with reading, initially with the smallest sizes of print and then later with larger print.</li><li>Sometimes people do not notice visual deterioration when one eye is affected, and the visual loss only becomes apparent when the second eye becomes affected. </li></ul></li><li><strong>Metamorphopsia </strong>— distortion of vision, where straight lines (such as window blinds) appear crooked, wavy, or bent. </li><li><strong>Scotoma</strong> — the person may describe a black or grey patch affecting their central field of vision. </li></ul></li><li><strong>Other symptoms that may be described by a person with AMD include: </strong><ul><li>Light glare. </li><li>Loss of (or decreased) contrast sensitivity (the ability to discern between different shades). </li><li>Size or colour of objects appearing different with each eye. </li><li>Abnormal dark adaptation (difficulty adjusting from bright to dim lighting). </li><li>Photopsia — a perception of flickering or flashing lights. </li><li>Visual hallucinations (Charles Bonnet syndrome) — these can occur with severe visual loss of any cause, including advanced AMD. Visual hallucinations are often not reported unless specifically asked about. </li></ul></li><li><strong>On examination:</strong><ul><li>Visual acuity may be reduced. </li><li>With fundoscopy by a general practitioner, signs may be difficult to detect, depending on the level of expertise. The following signs may be seen: <ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/background-information/definition/\">Drusen</a> — a frequent feature in the early stages of disease. </li><li>Pigmentary, exudative, haemorrhagic, or <a class=\"topic-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/background-information/definition/\">atrophic changes</a> affecting the macula. </li></ul></li></ul></li><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/management/suspected-amd/#primary-care-management\">Refer</a> urgently to an ophthalmologist for confirmation of the diagnosis if AMD is suspected.</strong></li></ul><!-- end field 93289efb-f241-41bd-a57c-d8cc4eea4765 --><!-- end item 699b52bf-44e7-4ff8-9229-3140f5ae056b -->","topic":{"id":"bb3e11cb-517f-5331-9de9-039d796fed2d","topicId":"819a45d3-fd1c-42c7-8420-27d4daf53cc2","topicName":"Macular degeneration - age-related","slug":"macular-degeneration-age-related","lastRevised":"Last revised in October 2020","chapters":[{"id":"8dda5709-9896-57f9-9907-7fb9c46fe863","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bb451071-7381-59cb-aa21-2b2bccafe2d2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5006d91f-871e-5987-a351-38613676d868","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b46dda65-9a23-5d6c-9afe-03e05a87cc3c","slug":"changes","fullItemName":"Changes"},{"id":"a82ab674-261f-5a3d-8d12-5c13643cd924","slug":"update","fullItemName":"Update"}]},{"id":"e40fe343-86d1-5303-af86-c3b22d664113","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"807a5294-312b-51b7-8a2b-2b7d9c18a2a2","slug":"goals","fullItemName":"Goals"},{"id":"875cd1b7-ea38-5e4d-b1ac-1c4d4e110927","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1c4bcbde-43f9-57c5-87d2-37e2a7bfc7b3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"73e19abc-9ba2-505a-aae8-23b40e76c49f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cb9a7aab-681a-5b78-aca6-dcb97a9ae535","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"25a06a16-e897-5cb6-bdf2-99705c2c3f77","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7cb3e392-3b5c-558a-988c-646bacf307bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"69a4bcc6-b18d-52c2-b7f8-b74b4bebf32c","slug":"definition","fullItemName":"Definition"},{"id":"e34a411a-f7c0-5084-965b-49ac89736d30","slug":"classification","fullItemName":"Classification"},{"id":"d537f969-c989-57cd-824a-d0718c657988","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4098eb73-c982-50a6-830c-61d7dc25c997","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c49a0066-054e-5666-9b2d-7bad39b079cc","slug":"prognosis","fullItemName":"Prognosis"},{"id":"1313d171-0d54-5814-baef-2c79e54a147e","slug":"complications","fullItemName":"Complications"}]},{"id":"5daaa827-5772-5a33-8675-cf20b916db2e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7fd2b2d6-9e86-5014-bc61-f30ce19d5712","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"fa4cdf98-731f-5fab-b1b9-802d0ad26a9e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"491fb145-6067-5e5d-b364-2a3d874dcbde","fullItemName":"Management","slug":"management","subChapters":[{"id":"623a85d0-3eef-5b46-a5a6-0c14facafc46","slug":"suspected-amd","fullItemName":"Scenario: Suspected AMD"},{"id":"1d91de12-c8ef-5335-9359-81816456fb81","slug":"confirmed-amd","fullItemName":"Scenario: Confirmed AMD"}]},{"id":"0c6673ad-62d1-59a7-93a7-dc791491644d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"81330a87-dcef-52cd-9707-efa0e22c0435","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"565ac27d-4e4d-5f6c-ba0a-bef0793f4f68","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"97a694f8-29e3-5e9b-9e46-68e52e2499d0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"adea819b-f313-5842-8936-3b1d2feee7ad","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e49d7e10-0bcd-5d89-b7f3-64d4ff858f1c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8059070a-a973-530d-8d9b-0e4cb14d5b65","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4ea345d9-fe7e-558f-b710-2bb252185ef8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5daaa827-5772-5a33-8675-cf20b916db2e","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"124d6723-74ad-53a0-9e7d-95316fc86063","slug":"basis-for-recommendation-d8e","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 0ccd7e2a-6dc0-4577-a287-5d642237353d --><h3>Basis for recommendation</h3><!-- end field 0ccd7e2a-6dc0-4577-a287-5d642237353d -->","summary":null,"htmlStringContent":"<!-- begin item d8e01d90-3c78-4c84-bb83-c1b16bbe2ad4 --><!-- begin field 2b401973-ff71-4327-be39-a8f62de1bc67 --><p>This information is largely based on the Royal College of Ophthalmologists (RCO) <em>Guidelines for the management of age-related macular degeneration (AMD)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">Royal College of Ophthalmologists, 2013</a>], the American Academy of Ophthalmology (AAO) guideline <em>Age-related macular degeneration preferred practice pattern</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">AAO, 2019</a>], the British Medical Journal (BMJ) best practice guide <em>Age-related macular degeneration</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">BMJ, 2018</a>], and expert opinion in a narrative review <em>Age-related macular degeneration: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">Cook, 2008</a>].</p><!-- end field 2b401973-ff71-4327-be39-a8f62de1bc67 --><!-- end item d8e01d90-3c78-4c84-bb83-c1b16bbe2ad4 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}